Archive — US — techcrunch
OpenAI researcher Miles Wang in talks to launch AI drug discovery startup valuedat $2B
Miles Wang, an OpenAI researcher, is leaving to launch an AI drug discovery startup valued at $2B, seeking $200M in funding. Several OpenAI colleagues may join him. The startup aims to develop AI models for drug repurposing, tapping into investor interest in AI's life sciences applications.
Key points
- Miles Wang is an OpenAI researcher known for AI in scientific discovery.
- He is starting a new AI drug discovery startup aiming for a $2B valuation.
- The startup plans to raise $200M with discussions led by Lightspeed Venture Partners.
- Investor interest in AI for life sciences is growing, exemplified by recent funding of similar startups.
- The new startup may focus on finding new uses for existing drugs, faster than developing new ones.
Why it matters
- The trend of using AI in drug discovery aligns with the growing focus on biotechnology and medical advancements.
- Recent funding rounds for startups like Chai Discovery and Isomorphic Labs indicate a booming market for AI in life sciences.
- The shift towards young, innovative founders in tech startups reflects broader trends in venture capital; this may influence similar future investments.
Wang's transition from OpenAI to launching a drug discovery startup highlights a promising intersection of AI and pharmaceuticals, reflecting broader trends in investment and innovation within the life sciences sector.